Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer
Loading...
Date
Authors
Roukos, D. H.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Type
Type of the conference item
Journal type
peer-reviewed
Educational material type
Conference Name
Journal name
J Clin Oncol
Book name
Book series
Book edition
Alternative title / Subtitle
Description
Description
Keywords
Antibodies, Monoclonal/*therapeutic use, Antibodies, Monoclonal, Humanized, Antineoplastic Agents/therapeutic use, Breast Neoplasms/*drug therapy/enzymology/metabolism/*pathology, Disease-Free Survival, Female, Humans, Neoplasm Staging, Receptor, erbB-2/*antagonists & inhibitors/immunology, Receptors, Estrogen/metabolism, Receptors, Progesterone/metabolism
Subject classification
Citation
Link
http://www.ncbi.nlm.nih.gov/pubmed/20406920
http://jco.ascopubs.org/content/28/17/e279.full.pdf
http://jco.ascopubs.org/content/28/17/e279.full.pdf
Language
en
Publishing department/division
Advisor name
Examining committee
General Description / Additional Comments
Institution and School/Department of submitter
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής